Alinaghi F, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19.

Article  PubMed  Google Scholar 

Shah K, et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2): e000588.

Article  PubMed  PubMed Central  Google Scholar 

Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.

Article  PubMed  Google Scholar 

Lindberg I, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in swedish routine clinical care. Acta Derm Venereol. 2020;100(18):adv00324.

Article  PubMed  Google Scholar 

Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

Article  PubMed  Google Scholar 

Nast A, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris—part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–98.

Article  PubMed  Google Scholar 

Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–66.

Article  PubMed  Google Scholar 

Savage L, et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheumatol. 2019;71(4):626–31.

Article  PubMed  Google Scholar 

Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheumatol. 2022;74(2):237–43.

Article  PubMed  Google Scholar 

Acosta Felquer ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74–9.

Article  PubMed  Google Scholar 

Gisondi P, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.

Article  PubMed  Google Scholar 

Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200–7.

Article  PubMed  Google Scholar 

Ham SP, et al. Validity of diagnostic codes for identification of psoriasis patients in Korea. Ann Dermatol. 2020;32(2):115–21.

Article  PubMed  PubMed Central  Google Scholar 

Lee M, Lee JW, Kim TG, Lee MG. Clinical features and treatment patterns of Korean patients with psoriatic arthritis: a retrospective single-center study. Korean J Dermatol. 2018;56(5):308–13.

Google Scholar 

Karmacharya P, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410–6.

Article  PubMed  PubMed Central  Google Scholar 

Karmacharya P, et al. Time to transition from psoriasis to psoriatic arthritis: a population-based study. Semin Arthritis Rheum. 2022;52: 151949.

Article  PubMed  Google Scholar 

Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323(23):2417–8.

Article  PubMed  Google Scholar 

Caso F, et al. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36(10):909–25.

Article  PubMed  Google Scholar 

Tarannum S, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513–26.

Article  PubMed  Google Scholar 

Dong G, et al. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. J Biopharm Stat. 2020;30(5):882–99.

Article  PubMed  PubMed Central  Google Scholar 

Yoshida K, et al. Multinomial extension of propensity score trimming methods: a simulation study. Am J Epidemiol. 2019;188(3):609–16.

Article  PubMed  Google Scholar 

Arnold BF, Ercumen A. Negative control outcomes: a tool to detect bias in randomized trials. JAMA. 2016;316(24):2597–8.

Article  PubMed  PubMed Central  Google Scholar 

VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167(4):268–74.

Article  PubMed  Google Scholar 

Meer E, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80–6.

Article  PubMed  Google Scholar 

Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159–68.

Article  PubMed  Google Scholar 

Yago T, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96.

Article  PubMed  PubMed Central  Google Scholar 

Fuseini H, et al. ERα signaling increased IL-17A production in Th17 cells by upregulating IL-23R expression, mitochondrial respiration, and proliferation. Front Immunol. 2019;10:2740.

Article  PubMed  PubMed Central  Google Scholar 

Lee E, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.

Article  PubMed  PubMed Central  Google Scholar 

Diels J, et al. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183(2):276–84.

Article  PubMed  PubMed Central  Google Scholar 

Papp KA, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60.

Article  PubMed  Google Scholar 

Mehrmal S, et al. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021;84(1):46–52.

Article  PubMed  Google Scholar 

Mease PJ, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024;10(1):e003423.

Article  PubMed  PubMed Central  Google Scholar 

Sbidian E, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.

PubMed  Google Scholar 

Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023;40(8):3410–33.

Article  PubMed  PubMed Central  Google Scholar 

Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database. JAMA Dermatol. 2022;158(5):513–22.

Article  PubMed  PubMed Central  Google Scholar 

Cozzani E, et al. Serial biologic therapies in psoriasis patients: a 12-year, single-center, retrospective observational study. J Am Acad Dermatol. 2020;82(1):37–44.